The proposed MCIDs and composite measure provide a standardized way to assess clinically relevant cognitive changes in preclinical Alzheimer's disease trials.
Answers are grounded in this paper and cite their sources.
May facilitate standardized cognitive endpoints in preclinical AD trials; leaves open prospective validation before routine adoption.
Our MCIDs may be applied in clinical practice or clinical trials for identifying whether a clinically relevant change has occurred. The composite measure can be useful as a clinically relevant cognitive test outcome in preclinical AD trials.
No takes yet. Share an insight, caveat, or question.
Borland et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: